Streetbeat News

Analyst Ratings

DOCU

Morgan Stanley analyst Josh Baer maintains an Underweight rating on DocuSign (NASDAQ:DOCU) and lowers the price target from $54 to $49.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 12:25 pm

DRH

Morgan Stanley analyst Stephen Grambling reiterated an Equal-Weight rating on Diamondrock Hospitality (NYSE:DRH) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 12:24 pm

ORA

Oppenheimer analyst Noah Kaye has reiterated an Outperform rating on Ormat Technologies (NYSE:ORA) and maintained a $96 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 12:23 pm

CHH

Morgan Stanley analyst Stephen Grambling maintains an Equal-Weight rating on Choice Hotels Intl (NYSE:CHH) and lowers the price target from $134 to $127.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 12:23 pm

CARG

CarGurus shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and a $29 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 12:22 pm

AVTX

Oppenheimer analyst Leland Gershell downgraded Avalo Therapeutics (NASDAQ:AVTX) from Outperform to Perform.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 12:22 pm

CCL

Morgan Stanley analyst Jamie Rollo maintains an Underweight rating on Carnival (NYSE:CCL) and raises the price target from $7 to $11.5.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 12:21 pm

MMM

Morgan Stanley analyst Joshua Pokrzywinski maintains an Underweight rating on 3M (NYSE:MMM) and lowers the price target from $102 to $100.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 12:20 pm

LBPH

Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 12:19 pm

ORTX

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Orchard Therapeutics (NASDAQ:ORTX) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 12:18 pm